Publications by authors named "S Rupoli"
Numerous cutting-edge immunotherapy approaches have been developed for hematological malignancies, such as immune-checkpoint inhibitors for lymphomas, chimeric antigen receptor (CAR)-T-cell treatments for B-cell cancers, and monoclonal antibody therapies for acute myeloid leukemia (AML). However, achieving similar breakthroughs in MPNs has proven challenging. The key obstacles include the absence of universally expressed and MPN-specific surface markers, significant cellular and molecular variability among both individual patients and across different MPN subtypes, and the failure of treatments to stimulate an anti-tumor immune response due to the immune system disruptions caused by the myeloid neoplasm.
View Article and Find Full Text PDFTopical chlormethine (CL) gel formulation was approved by the EMA in 2017 for the treatment of adult patients with mycosis fungoides (MF). To expand the knowledge on the management of MF, this paper provides an overview of clinical practice evidence about the MF diagnostic phase and a collection of clinical experiences to better characterize the use of CL gel in daily practice. Collected cases underline the importance of the concomitant biopsy and clinical evaluation in the diagnostic phase, with the contribution of a multidisciplinary team, and support the use of CL gel as a first-line or adjuvant treatment in selected patients.
View Article and Find Full Text PDFArticle Synopsis
- Amyloid Light Chain (AL) Amyloidosis is a rare disorder where misfolded proteins form insoluble fibrils that can accumulate in different organs, leading to serious health issues and potential fatality.
- The heart is the most commonly affected organ, and its involvement is often linked to worse outcomes, while the kidneys and liver can also be impacted, showcasing AL Amyloidosis as a multisystem disease.
- Budd-Chiari syndrome (BCS), a rare liver condition caused by blocked hepatic veins, can occasionally be linked to AL Amyloidosis due to amyloid protein buildup in the liver, presenting an unusual clinical scenario.
Article Synopsis
- - Myeloproliferative neoplasms (MPNs) are linked to unusual site thrombosis in about 40% of cases, complicating diagnosis due to overlapping symptoms with portal hypertension and bleeding issues.
- - Recent advancements in diagnostic techniques, including molecular markers, have improved the classification and prognosis of MPNs, emphasizing the need for mutation screening as a starting point for patients with splanchnic vein thrombosis.
- - A multidisciplinary approach is essential for accurate diagnosis and effective treatment, and establishing specialized care pathways can help manage risks associated with MPNs and related complications.